Sionna Therapeutics, Inc.
SIONHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Sionna Therapeutics, Inc. (SION) is listed under Biotechnology. With a market capitalization of $329.6M, it sits in small-cap territory. It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial.
Market Cap
$329.6M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-2.90
EPS (TTM)
$-2.15
EPS (Fwd)
$-2.52
ROE
-32.3%
ROA
-21.5%
Cash
$211.0M
Total Debt
$8.1M
Free CF
-$45.4M
52W Change
-70.7%
Annual Financials
Cash vs Debt
Where SION stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, SION finished 82.28% below its 150-day moving average ($36.45) and 82.81% below its 200-day moving average ($37.59). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SION overbought or oversold?
At the September 2, 2026 close, SION's RSI(14) was 52.5, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $211.0M in cash comfortably exceeding the $8.1M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$45.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -32.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With cash comfortably exceeding debt, SION has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Sionna Therapeutics, Inc. and its sector.